Fund managed: Polar Capital Biotechnology R USD
Total return over three years: 67.8%
In first place and leading the way in the biotech sector is Citywire AAA rated David Pinniger on the Polar Capital Biotechnology fund.
Pinniger has managed the fund since its launch. He joined Polar Capital in 2013 and has 17 years of industry experience.
The $206.3 million biotech fund is predominantly invested in the US, which accounts for 72.8% of the portfolio. Denmark and the UK are the next largest country exposures, making up 5.3% and 5.2% of the fund respectively.
The fund attracted the second highest net flows in the sector since the beginning of the year, beaten only by the Candriam fund, with net flows of CHF 59.26 million.
Over three years to the end of July 2017, the Polar Capital Biotechnology fund generated a total return of 67.8%, almost doubling the benchmark, the NASDAQ Biotechnology TR, which returned 36.56% over the same period.